Scinai Immunotherapeutics Ltd. (SCNI) Stock Analysis and Metrics

Scinai Immunotherapeutics

NASDAQ: SCNI

$0.23 ▼ -0.02 (-6.88%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap3.54 Bn

P/E-567.92

P/S2,410.19

Div. Yield0.00

Total Debt (Qtr)641,000.00

Revenue Growth (1y) (Qtr)-16.55

Add ratio to table…

About

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company specializing in the development of innovative therapeutics in inflammation and immunology, alongside a contract development and manufacturing organization (CDMO) business. The company operates at the intersection of drug discovery and biopharmaceutical services, leveraging its expertise in antibody-based therapies and manufacturing capabilities to address unmet medical needs in dermatological and inflammatory conditions. Its pipeline includes novel monoclonal antibodies and NanoAbs, a platform of nanosized antibody fragments with potential applications across multiple therapeutic areas.

Scinai Immunotherapeutics Ltd. generates revenue primarily through its CDMO business, which provides integrated development and manufacturing services to small and emerging biotech companies. These services include analytical method development, process optimization, and cGMP manufacturing for clinical-stage biologics and small molecules. The company also pursues non-dilutive funding, such as grants, to advance its internal research and development programs, which focus on therapeutic candidates like PC111 and NanoAb-based treatments for psoriasis, pemphigus, and other inflammatory diseases. While the CDMO segment currently drives revenue, the company’s long-term growth may depend on the successful commercialization of its proprietary drug candidates.

The company operates through the following segments:

• Scinai R&D: This segment focuses on the discovery and development of innovative therapeutics in inflammation and immunology. It includes the PC111 program, a fully human monoclonal antibody targeting severe dermatological conditions such as pemphigus, Stevens-Johnson Syndrome, and toxic epidermal necrolysis. Additionally, the segment advances a pipeline of NanoAbs, nanosized antibody fragments developed in collaboration with the Max Planck Society and the University Medical Center Göttingen, targeting clinically validated pathways like IL-17 and IL-13 for conditions such as psoriasis, psoriatic arthritis, and asthma. The R&D segment also evaluates strategic acquisitions and in-licensing opportunities to expand its therapeutic portfolio.

• Contract Development and Manufacturing Organization (CDMO): Operating through the subsidiary Scinai Biopharma Services Ltd., this segment provides end-to-end development and manufacturing services to biopharmaceutical clients. Services include early-stage analytical and process development, cGMP manufacturing for biologics and small molecules, and fill-and-finish operations. The CDMO business leverages facilities in Jerusalem and Yavne, Israel, to support clients from preclinical development through clinical-stage production. The segment also benefits from a strategic collaboration with Recipharm, enabling lifecycle support for client programs from early development to late-stage manufacturing.

Scinai Immunotherapeutics Ltd. occupies a niche position within the biopharmaceutical industry, competing with both large pharmaceutical companies and specialized biotech firms in the development of antibody-based therapeutics. Its competitive advantages include a dual business model that combines proprietary R&D with CDMO services, providing operational flexibility and revenue diversification. The company’s NanoAbs platform, developed in partnership with leading academic institutions, offers potential advantages such as strong binding affinity, thermal stability, and flexible administration routes, which may differentiate its pipeline from traditional monoclonal antibodies. Additionally, its CDMO business benefits from advanced manufacturing capabilities and a strategic collaboration with Recipharm, positioning it as a preferred partner for early-stage biotech companies. Key competitors include firms developing IL-17 and IL-13 inhibitors, as well as CDMO providers with similar service offerings.

The company’s customer base is divided between its CDMO and R&D segments. The CDMO business primarily serves small and emerging biotechnology companies, particularly in Israel and the United States, providing development and manufacturing services for clinical-stage programs. Specific client names are not disclosed, but the segment has secured multiple engagements, including repeat projects and contracts under negotiation. The R&D segment, while not yet commercialized, targets patients with severe dermatological and inflammatory conditions, such as pemphigus and psoriasis, where existing treatments are limited or associated with significant side effects. Future commercialization efforts may involve partnerships with pharmaceutical companies equipped to market and distribute its therapeutic candidates.

Investment Thesis

▲ Bull case

Scinai's strategic acquisition of Recipharm Israel in February 2026 established a two-site CDMO platform with biologics manufacturing in Jerusalem and small-molecule API production in Yavne, creating a vertically integrated offering that can support customers from early-stage development through commercial manufacturing via Recipharm's global network. This integration is underpinned by the corporate reorganization announced in April 2026 that formally separated CDMO and R&D activities, enabling Scinai Biopharma Services to operate as a focused, revenue-generating platform while allowing the parent company to maintain a lean, capital-efficient R&D structure focused on advancing PC111 and NanoAbs programs. The separation enhances accountability and scalability, positioning the CDMO business as a standalone growth engine capable of generating consistent revenue to fund R&D initiatives without relying solely on dilutive financing. The market may be underestimating how this structural shift creates a self-sustaining model where CDMO cash flows can de-risk pipeline advancement, particularly as the company pursues non-dilutive funding for its lead assets.
The company's aggressive pursuit of non-dilutive funding represents a significant catalyst that the market is overlooking, exemplified by the revised €12 million FENG grant application for PC111 submitted in March 2026, which would cover 80% of a €15 million integrated R&D program targeting proof-of-concept in severe orphan dermatologic indications like pemphigus vulgaris and SJS/TEN. If awarded, this grant would substantially de-risk PC111's development while preserving balance sheet flexibility and minimizing shareholder dilution, especially given the high unmet medical need in these indications that could support accelerated regulatory pathways. Additionally, Scinai secured expanded support from the Israel Innovation Authority in February 2026 for its robotic aseptic fill-and-finish platform, utilizing the full NIS 5 million grant budget (66% non-dilutive) to advance EU GMP Annex 1-compliant sterilization capabilities at its Jerusalem site by Q3 2026. These combined non-dilutive initiatives reduce the capital burden on shareholders while accelerating technological differentiation in sterile biologics manufacturing, a critical advantage in attracting blue-chip clients seeking reliable, high-compliance CDMO partners.
Scinai's CDMO business demonstrated tangible momentum in 2025, with revenues doubling year-over-year to $1.3 million from $0.7 million, driven by expanded activities among biotech clients in Israel and the United States, even as R&D spending was strategically reduced to $2.4 million from $5.5 million through reprioritization of the pipeline around PC111 as the lead value driver. This operational efficiency—achieved while maintaining customer program execution—reflects successful cost discipline and highlights the scalability of the CDMO model post-Repharm acquisition. The company's ability to grow CDMO revenue while streamlining R&D costs suggests that the integrated platform is beginning to generate operating leverage, with the Yavne site's small-molecule capabilities broadening the addressable market beyond biologics. The market may be failing to recognize that this revenue inflection point, combined with the Recipharm collaboration's downstream economics (including referral-based royalties), could transform the CDMO business into a predictable cash flow generator that funds R&D milestones and reduces dependence on volatile biotech financing cycles.

Scinai's strategic acquisition of Recipharm Israel in February 2026 established a two-site CDMO platform with biologics manufacturing in Jerusalem and small-molecule API production in Yavne, creating a vertically integrated offering that can support customers from early-stage development through commercial manufacturing via Recipharm's global network. This integration is underpinned by the corporate reorganization announced in April 2026 that formally separated CDMO and R&D activities, enabling Scinai Biopharma Services to operate as a focused, revenue-generating platform while allowing the parent company to maintain a lean, capital-efficient R&D structure focused on advancing PC111 and NanoAbs programs. The separation enhances accountability and scalability, positioning the CDMO business as a standalone growth engine capable of generating consistent revenue to fund R&D initiatives without relying solely on dilutive financing. The market may be underestimating how this structural shift creates a self-sustaining model where CDMO cash flows can de-risk pipeline advancement, particularly as the company pursues non-dilutive funding for its lead assets.
The company's aggressive pursuit of non-dilutive funding represents a significant catalyst that the market is overlooking, exemplified by the revised €12 million FENG grant application for PC111 submitted in March 2026, which would cover 80% of a €15 million integrated R&D program targeting proof-of-concept in severe orphan dermatologic indications like pemphigus vulgaris and SJS/TEN. If awarded, this grant would substantially de-risk PC111's development while preserving balance sheet flexibility and minimizing shareholder dilution, especially given the high unmet medical need in these indications that could support accelerated regulatory pathways. Additionally, Scinai secured expanded support from the Israel Innovation Authority in February 2026 for its robotic aseptic fill-and-finish platform, utilizing the full NIS 5 million grant budget (66% non-dilutive) to advance EU GMP Annex 1-compliant sterilization capabilities at its Jerusalem site by Q3 2026. These combined non-dilutive initiatives reduce the capital burden on shareholders while accelerating technological differentiation in sterile biologics manufacturing, a critical advantage in attracting blue-chip clients seeking reliable, high-compliance CDMO partners.
Scinai's CDMO business demonstrated tangible momentum in 2025, with revenues doubling year-over-year to $1.3 million from $0.7 million, driven by expanded activities among biotech clients in Israel and the United States, even as R&D spending was strategically reduced to $2.4 million from $5.5 million through reprioritization of the pipeline around PC111 as the lead value driver. This operational efficiency—achieved while maintaining customer program execution—reflects successful cost discipline and highlights the scalability of the CDMO model post-Repharm acquisition. The company's ability to grow CDMO revenue while streamlining R&D costs suggests that the integrated platform is beginning to generate operating leverage, with the Yavne site's small-molecule capabilities broadening the addressable market beyond biologics. The market may be failing to recognize that this revenue inflection point, combined with the Recipharm collaboration's downstream economics (including referral-based royalties), could transform the CDMO business into a predictable cash flow generator that funds R&D milestones and reduces dependence on volatile biotech financing cycles.

▼ Bear case

Scinai faces persistent and material risks related to its Nasdaq listing compliance, having received a formal notification on March 12, 2026, that its ADSs traded below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2), with an initial compliance period extending until September 8, 2026. Despite management's stated intent to regain compliance, the company has not disclosed any specific reverse stock split plan or substantive catalyst to sustainably elevate the share price above the threshold, leaving investors exposed to the risk of delisting, which would severely impair liquidity, increase financing costs, and erode institutional confidence. The market may be ignoring how this regulatory overhang compounds existing financial weaknesses, particularly given the company's history of relying on non-recurring financial events—like the $13.4 million financial income from loan conversion in 2024 that did not recur in 2025—to mask underlying operational losses, as evidenced by the $8.3 million net loss in 2025 despite only $1.3 million in revenue.
The company's heavy reliance on securing non-dilutive grant funding, particularly the €12 million FENG grant for PC111 and expanded IIA support for sterile manufacturing, introduces significant execution risk, as these awards are subject to competitive review, potential delays, or outright rejection, with no guarantee of approval timelines aligning with operational needs. Scinai's candor in its forward-looking statements acknowledges that failure to obtain or delays in receiving such funding could derail its R&D programs and CDMO expansion plans, yet the market may be overestimating the likelihood of success given the company's limited scale and track record in securing large-scale international grants. Furthermore, the appointment of Eilon Elmalem as Site Head of the Yavne facility in May 2026, while bolstered by his Merck and Sigma-Aldrich experience, raises concerns about integration depth, as his prior role was as an external consultant rather than a long-term operational leader, potentially leaving gaps in institutional knowledge during the critical post-acquisition stabilization phase of the Recipharm Israel site.
Scinai's R&D pipeline remains nascent and unproven, with PC111 still contingent on option agreement terms with PinCell S.r.l. (extended to August 31, 2026, for fulfillment and September 30, 2026, for exercise) and NanoAbs programs dependent on ongoing collaboration with the Max Planck Society, yet the company has disclosed no near-term clinical milestones, pharmacokinetic data, or partnership commitments to validate therapeutic potential. The shift toward oral peptide and small molecule therapies highlighted in its May 2026 participation at the Dermatology Drug Development Summit Europe underscores a strategic vulnerability: if oral modalities gain traction in immunology, Scinai's injectable biologic-focused pipeline could face displacement in key dermatology indications, especially given the acknowledged challenges of oral therapies—such as bioavailability limitations and treatment adherence dependence—that the company itself admits could undermine durability of response. This strategic misalignment, combined with the absence of late-stage clinical data or regulatory engagement for any pipeline asset, leaves the R&D business highly susceptible to failure, with no near-term revenue offset from therapeutic commercialization to balance CDMO investments.

Scinai faces persistent and material risks related to its Nasdaq listing compliance, having received a formal notification on March 12, 2026, that its ADSs traded below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2), with an initial compliance period extending until September 8, 2026. Despite management's stated intent to regain compliance, the company has not disclosed any specific reverse stock split plan or substantive catalyst to sustainably elevate the share price above the threshold, leaving investors exposed to the risk of delisting, which would severely impair liquidity, increase financing costs, and erode institutional confidence. The market may be ignoring how this regulatory overhang compounds existing financial weaknesses, particularly given the company's history of relying on non-recurring financial events—like the $13.4 million financial income from loan conversion in 2024 that did not recur in 2025—to mask underlying operational losses, as evidenced by the $8.3 million net loss in 2025 despite only $1.3 million in revenue.
The company's heavy reliance on securing non-dilutive grant funding, particularly the €12 million FENG grant for PC111 and expanded IIA support for sterile manufacturing, introduces significant execution risk, as these awards are subject to competitive review, potential delays, or outright rejection, with no guarantee of approval timelines aligning with operational needs. Scinai's candor in its forward-looking statements acknowledges that failure to obtain or delays in receiving such funding could derail its R&D programs and CDMO expansion plans, yet the market may be overestimating the likelihood of success given the company's limited scale and track record in securing large-scale international grants. Furthermore, the appointment of Eilon Elmalem as Site Head of the Yavne facility in May 2026, while bolstered by his Merck and Sigma-Aldrich experience, raises concerns about integration depth, as his prior role was as an external consultant rather than a long-term operational leader, potentially leaving gaps in institutional knowledge during the critical post-acquisition stabilization phase of the Recipharm Israel site.
Scinai's R&D pipeline remains nascent and unproven, with PC111 still contingent on option agreement terms with PinCell S.r.l. (extended to August 31, 2026, for fulfillment and September 30, 2026, for exercise) and NanoAbs programs dependent on ongoing collaboration with the Max Planck Society, yet the company has disclosed no near-term clinical milestones, pharmacokinetic data, or partnership commitments to validate therapeutic potential. The shift toward oral peptide and small molecule therapies highlighted in its May 2026 participation at the Dermatology Drug Development Summit Europe underscores a strategic vulnerability: if oral modalities gain traction in immunology, Scinai's injectable biologic-focused pipeline could face displacement in key dermatology indications, especially given the acknowledged challenges of oral therapies—such as bioavailability limitations and treatment adherence dependence—that the company itself admits could undermine durability of response. This strategic misalignment, combined with the absence of late-stage clinical data or regulatory engagement for any pipeline asset, leaves the R&D business highly susceptible to failure, with no near-term revenue offset from therapeutic commercialization to balance CDMO investments.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Timing of Transfer of Good or Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Timing of Transfer of Good or Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password